Excellent safety, efficacy, and tolerability profiles have resulted in the rapid integration of oral tyrosine kinase inhibitors into most facets of the treatment of gastrointestinal stromal tumors (GIST).
James C. Watson, MD
Advertisement
Articles by James C. Watson, MD
Advertisement
Latest Updated Articles
- Perioperative Tyrosine Kinase Inhibitors for GIST: Standard . . . or an Idea That Needs Further Investigation?
Published: January 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
2
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
3
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
4
BL-B01D1 Shows Preliminary Efficacy, Favorable Safety in Urothelial Cancer
5
